Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 203-212

  Zhao, Qi Hong ^a   Zhang, Ying ^a   Liu, Yun ^a   Wang, Hui Li ^a   Shen, Yuan Yuan ^a   Yang, Wen Jun ^a   Wen, Long Ping ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Angiogenesis; Anticancer effect; Melanoma; Realgar nanoparticles; Transdermal drug delivery

Indexed keywords

ARSENIC DERIVATIVE; NANOPARTICLE; REALGAR; TETRAARSENIC TETRASULFIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG PENETRATION; FEEDING BEHAVIOR; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LIVER INJURY; MALE; MELANOMA; MOTOR ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN IRRITATION; TUMOR VOLUME;

ADMINISTRATION, CUTANEOUS; ANIMALS; ARSENICALS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NANOPARTICLES; SKIN NEOPLASMS; SULFIDES;

EID: 77956926270     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9192-1     Document Type: Article

References (35)

1. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 2004;150:179-85. doi:10.1111/j.1365-2133.2004. 05708.x.
2. Jemal A, Siegel R, Ward E, Murray T, Xu JQ, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66. doi: 10.3322/canjclin.57.1.43.
3. Yang L, Parkin DM, Ferlay J, Li L, Chen YD. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 2005;14:243-50. doi: 10.1158/1055-9965.EPI-04-0680.
4. Anonymous. The inner canon of Emperor Huang. Beijing: Chinese Medical Ancient Books Publishing House; 2003.
5. The Cooperation Group of Phase II Clinical Trial of Compound Huangdai Tablet, Qian LS, Zhao YZ. Phase II clinical trial of compound Huangdai tablet in newly diagnosed acute promyelocytic leukemia. Chin J Hematol. 2006;27:801-4.
6. Frankenberger WT. Environmental chemistry of arsenic. 1st ed. New York: Marcel Dekker Inc; 2002.
7. Lu DP, Wang Q. Current study of APL treatment in China. Int J Hematol. 2002;76:316-8.
8. Lu DP, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR, et al. Tetraarsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood. 2002;99:3136-43. doi:10.1182/ blood.V99.9.3136.
9. Zhu J, Chen Z, Lallemand-Breitenbach V, de Theo H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002;2:705-13. doi:10.1038/nrc887. (Pubitemid 37328921)
10. Deng Y, Xu HB, Huang KX, Yang XL, Xie CS, Wu J. Size effects of realgar particles on apoptosis in a human umbilical vein endothelial cell line: ecv-304. Pharmacol Res. 2001;44:513-8. doi:10.1006/phrs.2001.0885. (Pubitemid 34019154)
11. Wang XB, Xi RG, Zhang ZR, Wang JG, Yao W. Study on pharmacokinetics of nanoparticle realgar powders in rabbit (in Chinese). Pharmaceutical J PLA. 2002;18:324-6.
12. Liu J, Lu YF,WuQ, Goyer RA, Waalkes MP. Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J Pharmaco Exp Ther. 2008;326:363-8. doi:10.1124/jpet.108.139543.
13. Hu J, Fang J, Dong Y, Chen SJ, Chen Z. Arsenic in cancer therapy. Anti-cancer Drug. 2005;16:119-26. doi:10.1097/0000 1813-200502000-00002.
14. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov. 2004;3:115-24. doi:10.1038/nrd1304. (Pubitemid 38239773)
15. Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov Today. 2004;9:697-703. doi:10.1016/S1359-6446(04)03180-0. (Pubitemid 39070282)
16. Kung AL, Wang S, Klco JM, Kaelin WG, et al. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med. 2000;6:1335-40. doi:10.1038/82146. (Pubitemid 32001016)
17. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6:273-86. doi:10.1038/ nrd2115. (Pubitemid 46505878)
18. Peter V, Oliver T, Michael H. Treatment resistance of solid tumors. Med Oncol. 2001;18:243-59. doi:10.1385/MO:18:4:243. (Pubitemid 34044509)
19. Keshet E, Ben-Sasson SA. Anticancer drug targets: approaching angiogenesis. J Clin Invest. 1999;104:1497-501. doi:10.1172/ JCI8849.
20. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9:677-84. doi:10.1038/ nm0603-677.
21. Bocci G, Falcone A, Fioravanti A, Orlandi P, Paolo AD, Fanelli G, et al. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer. 2008;98:1619-29. doi:10.1038/ sj.bjc.6604352.
22. Wu JZ, Ho PC. Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding. Eur J Pharm Sci. 2006;29:35-44. doi:10.1016/j.ejps. 2006.05.002.
23. Luo LY, Huang J, Gou BD, Zhang TL, Wang K. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by arsenic sulphide: Involvement of serine/threonine protein phosphatases. Leukemia Res. 2006;30:1399-405. doi: 10.1016/j.leukres.2006.03.016. (Pubitemid 44316859)
24. Menon C, Polin GM, Prabakaran I, Hsi A, Cheung C, Culver JP, et al. An integrated approach to measuring tumor oxygen status using human melanoma Xenografts as a model. Cancer Res. 2003;63:7232-40.
25. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 2002;1:1243-53.
26. Selvakumaran M, Yao KS, Feldman MD, O'Dwyer PJ. Anticancer effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol. 2008;75:627-38. doi:10.1016/j.bcp. 2007.09.029.
27. Tse WP, Che CT, Ken L, Lin ZX. Evaluation of the anti-proliferative properties of selected psoriasis-treating Chinese medicines on cultured HaCaT cells. J Ethnopharmacol. 2006;108:133-41. doi:10.1016/j.jep.2006.04.023. (Pubitemid 44498993)
28. Ding HF, Fisher DE. Induction of apoptosis in cancer: new therapeutic opportunities. Ann Med. 2002;34:451-69. doi: 10.1080/078538902321012405. (Pubitemid 36026777)
29. Lee SH, Ryu JK, Lee KY, Woo SM, Park JK, Yoo JW, et al. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett. 2008;259:39-49. doi:10.1016/j.canlet.2007.09. 015. (Pubitemid 350235089)
30. Jiang XH, Wong BCY, Yuen ST, Jiang SH, Cho CH, Lai KC, et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer. 2001;15:173-9. doi:10.1002/1097-0215(200002)9999: 9999<::AID-IJC1039>3.0.CO;2-D.
31. YM Li, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res. 1999;59:776-80.
32. 21, and apoptosis. Cancer Res. 2000;60:3065-7301.
33. Leung J, Pang A, Yuen WH, Kwong YL, Tse EWC. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood. 2007;109:740-6. doi: 10.1182/blood-2006-04-019588. (Pubitemid 46105976)
34. Sintov AC, Wormser U. Topical iodine facilitates transdermal delivery of insulin. J Control Release. 2007;118:185-8. doi: 10.1016/j.jconrel.2006.12.006. (Pubitemid 46343670)
35. Marie V. Mechanisms of arsenic biotransformation. Toxicology. 2002;181:211-7. doi:10.1016/S0300-483X(02)00285-8. (Pubitemid 36015701)